[go: up one dir, main page]

BRPI0919268A8 - Aptâmero que se liga ao ngf e medicamento - Google Patents

Aptâmero que se liga ao ngf e medicamento

Info

Publication number
BRPI0919268A8
BRPI0919268A8 BRPI0919268A BRPI0919268A BRPI0919268A8 BR PI0919268 A8 BRPI0919268 A8 BR PI0919268A8 BR PI0919268 A BRPI0919268 A BR PI0919268A BR PI0919268 A BRPI0919268 A BR PI0919268A BR PI0919268 A8 BRPI0919268 A8 BR PI0919268A8
Authority
BR
Brazil
Prior art keywords
aptamer
ngf
drug
inhibitory activity
activity against
Prior art date
Application number
BRPI0919268A
Other languages
English (en)
Inventor
Jin Ling
Miyakawa Shin
Fujiwara Masatoshi
Nakamura Yoshikazu
Hiramatsu Hisanao
Original Assignee
Fujimoto Seiyaku Kk
Ribomic Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fujimoto Seiyaku Kk, Ribomic Inc filed Critical Fujimoto Seiyaku Kk
Publication of BRPI0919268A2 publication Critical patent/BRPI0919268A2/pt
Publication of BRPI0919268A8 publication Critical patent/BRPI0919268A8/pt
Publication of BRPI0919268B1 publication Critical patent/BRPI0919268B1/pt
Publication of BRPI0919268B8 publication Critical patent/BRPI0919268B8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/115—Aptamers, i.e. nucleic acids binding a target molecule specifically and with high affinity without hybridising therewith ; Nucleic acids binding to non-nucleic acids, e.g. aptamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C07K1/22—Affinity chromatography or related techniques based upon selective absorption processes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/16—Aptamers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Analytical Chemistry (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

APTÂMERO PARA NGF E USO DESTE. A presente invenção refere-se a um aptâmero tendo uma atividade inibitória contra NGF; um complexo contendo um aptâmero tendo uma atividade de ligação ou atividade inibitória contra NGF e uma substância funcional (por exemplo, substâncias de afinidade, substâncias de etiquetação, enzimas, veículos de distribuição de fármaco, fármacos e similares); um medicamento, um agente diagnóstico, um agente de etiquetação e similares contendo um aptâmero tendo uma atividade de ligação ou atividade inibitória contra NGF, ou um complexo contendo o aptâmero e a substância funcional; e similares.
BRPI0919268A 2008-09-24 2009-09-18 aptâmero que se liga ao ngf e medicamento BRPI0919268B8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2008-244982 2008-09-24
JP2008244982 2008-09-24
PCT/JP2009/066457 WO2010035725A1 (ja) 2008-09-24 2009-09-18 Ｎｇｆに対するアプタマー及びその使用

Publications (4)

Publication Number Publication Date
BRPI0919268A2 BRPI0919268A2 (pt) 2017-11-07
BRPI0919268A8 true BRPI0919268A8 (pt) 2018-02-06
BRPI0919268B1 BRPI0919268B1 (pt) 2021-01-12
BRPI0919268B8 BRPI0919268B8 (pt) 2021-05-25

Family

ID=42059724

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0919268A BRPI0919268B8 (pt) 2008-09-24 2009-09-18 aptâmero que se liga ao ngf e medicamento

Country Status (16)

Country Link
US (1) US10260070B2 (pt)
EP (1) EP2354225B1 (pt)
JP (1) JP5602020B2 (pt)
KR (1) KR101694559B1 (pt)
CN (1) CN102171339B (pt)
AU (1) AU2009297626B2 (pt)
BR (1) BRPI0919268B8 (pt)
CA (1) CA2738129C (pt)
DK (1) DK2354225T3 (pt)
ES (1) ES2543222T3 (pt)
HU (1) HUE026595T2 (pt)
IL (1) IL211929A0 (pt)
MX (1) MX2011003144A (pt)
RU (1) RU2011116175A (pt)
WO (1) WO2010035725A1 (pt)
ZA (1) ZA201102682B (pt)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8975026B2 (en) 2007-01-16 2015-03-10 Somalogic, Inc. Method for generating aptamers with improved off-rates
CA2808233C (en) 2010-03-03 2017-07-11 Somalogic, Inc. Aptamers to 4-1bb and their use in treating diseases and disorders
PL2551346T3 (pl) * 2010-03-24 2016-07-29 Ribomic Inc Aptamer dla NGF i jego zastosowanie
CA2797188C (en) * 2010-04-12 2020-03-31 Somalogic, Inc. 5-position modified pyrimidines and their use
JP5696830B2 (ja) * 2010-04-27 2015-04-08 株式会社アップウェル Ｐａｒ−２活性化阻害物質
JP2012024026A (ja) * 2010-07-23 2012-02-09 Tdk Corp Ｓｍ菌特異的アプタマー、Ｓｍ菌増殖抑制剤及びＳｍ菌の検出方法
SI2611775T1 (sl) 2010-08-31 2017-01-31 Bionure Farma, S.L. Agonisti nevrotrofinskih receptorjev in njihova uporaba kot zdravil
CN103946381B (zh) * 2011-09-28 2017-06-23 力博美科股份有限公司 Ngf适体及其应用

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5660985A (en) * 1990-06-11 1997-08-26 Nexstar Pharmaceuticals, Inc. High affinity nucleic acid ligands containing modified nucleotides
ATE318832T1 (de) * 1990-06-11 2006-03-15 Gilead Sciences Inc Verfahren zur vervendung von nukleinsäureliganden
PT668931E (pt) 1992-09-29 2006-05-31 Gilead Sciences Inc Ligandos de acidos nucleicos e metodos para producao dos mesmos
WO1995007364A1 (en) 1993-09-08 1995-03-16 Nexstar Pharmaceuticals, Inc. Nucleic acid ligands and improved methods for producing the same
US20030054360A1 (en) 1999-01-19 2003-03-20 Larry Gold Method and apparatus for the automated generation of nucleic acid ligands
US7638464B2 (en) * 1999-04-26 2009-12-29 Biocept, Inc. Three dimensional format biochips
EP1265995A2 (en) * 2000-02-11 2002-12-18 Ribozyme Pharmaceuticals, Inc. Method and reagent for the modulation and diagnosis of cd20 and nogo gene expression
US20030077251A1 (en) * 2001-05-23 2003-04-24 Nicolas Escriou Replicons derived from positive strand RNA virus genomes useful for the production of heterologous proteins
US20050043256A1 (en) * 2001-07-30 2005-02-24 Isis Pharmaceuticals, Inc. Antisense modulation of stearoyl-CoA desaturase expression
US20050215506A1 (en) * 2001-12-20 2005-09-29 Bennett C F Modulation of tyrosinase expression
EP1481090A4 (en) 2002-02-15 2006-08-09 Somalogic Inc METHOD AND REAGENTS FOR DETECTING BINDING OF TARGET MOLECULES BY NUCLEIC ACID ELECTRODES
ZA200502612B (en) 2002-10-08 2007-07-25 Rinat Neuroscience Corp Methods for treating post-surgical pain by administering a nerve crowth factor antagonist and compositions containing the same
UA80447C2 (en) 2002-10-08 2007-09-25 Methods for treating pain by administering nerve growth factor antagonist and opioid analgesic
WO2005000194A2 (en) 2002-10-08 2005-01-06 Rinat Neuroscience Corp. Methods for treating post-surgical pain by administering an anti-nerve growth factor antagonist antibody and compositions containing the same
US7250496B2 (en) * 2002-11-14 2007-07-31 Rosetta Genomics Ltd. Bioinformatically detectable group of novel regulatory genes and uses thereof
US7569364B2 (en) 2002-12-24 2009-08-04 Pfizer Inc. Anti-NGF antibodies and methods using same
MXPA05008815A (es) 2003-02-19 2006-05-25 Rinat Neuroscience Corp Metodos para tratar el dolor al administrar un antagonista del factor de crecimiento de nervios y un farmaco antiinflamatorio no esteroidal y composiciones que contienen los mismos.
US20050136395A1 (en) * 2003-05-08 2005-06-23 Affymetrix, Inc Methods for genetic analysis of SARS virus
US7888497B2 (en) * 2003-08-13 2011-02-15 Rosetta Genomics Ltd. Bioinformatically detectable group of novel regulatory oligonucleotides and uses thereof
KR101504729B1 (ko) 2004-04-07 2015-03-19 리나트 뉴로사이언스 코프. 신경성장인자 길항제의 투여에 의한 골암 통증 치료용 약학적 조성물
US7592441B2 (en) * 2004-10-04 2009-09-22 Rosetta Genomics Ltd Liver cancer-related nucleic acids
UA100847C2 (uk) 2006-11-14 2013-02-11 Рибомик Инк. Аптамер проти мідкайну і його застосування
JP5012135B2 (ja) 2007-03-28 2012-08-29 コニカミノルタアドバンストレイヤー株式会社 超深度画像生成装置
US8440801B2 (en) 2008-07-14 2013-05-14 The University Of Tokyo Aptamer against IL-17 and use thereof

Also Published As

Publication number Publication date
IL211929A0 (en) 2011-06-30
ZA201102682B (en) 2012-06-27
EP2354225B1 (en) 2015-04-22
US20110251266A1 (en) 2011-10-13
CA2738129A1 (en) 2010-04-01
RU2011116175A (ru) 2012-10-27
JP5602020B2 (ja) 2014-10-08
BRPI0919268B8 (pt) 2021-05-25
EP2354225A9 (en) 2012-06-27
US10260070B2 (en) 2019-04-16
EP2354225A4 (en) 2012-03-21
CN102171339B (zh) 2017-06-09
CN102171339A (zh) 2011-08-31
BRPI0919268A2 (pt) 2017-11-07
ES2543222T3 (es) 2015-08-17
AU2009297626A1 (en) 2010-04-01
EP2354225A1 (en) 2011-08-10
MX2011003144A (es) 2011-05-19
KR101694559B1 (ko) 2017-01-09
DK2354225T3 (en) 2015-06-29
WO2010035725A1 (ja) 2010-04-01
AU2009297626B2 (en) 2016-01-14
CA2738129C (en) 2017-11-14
HUE026595T2 (hu) 2016-06-28
BRPI0919268B1 (pt) 2021-01-12
JPWO2010035725A1 (ja) 2012-02-23
AU2009297626A2 (en) 2011-05-19
KR20110059888A (ko) 2011-06-07

Similar Documents

Publication Publication Date Title
BRPI0919268A8 (pt) Aptâmero que se liga ao ngf e medicamento
MY147374A (en) Aptamer against midkine and use thereof
BR112014005543A2 (pt) sistema de descarte de medicação geral
BRPI0908208A2 (pt) Composto derivado de oxazolidinona, medicamento, composição farmacêutica que o contém e uso desse composto.
BRPI0716196A2 (pt) Sistemas de distribuição de fármacos que compreendem soluções sólidas de fármacos fracamente básicos.
UY32764A (es) Preparaciones insulinicas que comprenden metionina
MX2009002937A (es) Metodo y sistema para infusion controlada de substancias terapeuticas.
BR112012010534A2 (pt) "dispositivo de fornecimento de fármaco e método de montagem"
BRPI0814252B8 (pt) composição farmacêutica aquosa estável compreendendo natalizumabe, dose unitária, e seringa pré-cheia
BR112012027651A2 (pt) método, e, sistema
WO2007109184A3 (en) Anti-cancer activity augmentation compounds and formulations and methods of use thereof
WO2008112164A3 (en) Mitochondrial aldehyde dehydrogenase-2 modulators and methods of use thereof
BRPI0517569A (pt) uso de um ligando, ligando, composição farmacêutica, e, dispositivo de distribuição de drogas
BRPI0906478B8 (pt) anticorpo anti-nr10, seu uso e composição farmacêutica que o compreende
BRPI0821110B8 (pt) anticorpo de neutralização de anti-nr10/il31ra, composição farmacêutica compreendendo o referido anticorpo e uso do mesmo
CL2008000377A1 (es) Compuestos derivados de ciclos fusionados sustituidos; agente farmaceutico que comprende a dichos compuestos; y uso para la prevencion o tratamiento de la diabetes.
BR112012013975A2 (pt) anticorpos monoclonais que se ligam b7h6 e usos dos mesmo
CR10032A (es) Preparación sólida
BRPI0717369A2 (pt) Composto, medicamento, composição farmacêutica que o contém e uso do composto.
BR112012026724A2 (pt) combinação de fármcos com pró-fármacos ligados à proteína
BRPI0907892A2 (pt) Composto antibiótico azatricíclico, medicamento, composição farmacêutica que o contém e uso do mesmo
AR077049A1 (es) Aptamero contra quimasa y su uso
CL2014003148A1 (es) Composición farmacéutica acuosa que contiene un agente terapéutico biológico y guanidina o un derivado de la guanidina y una inyección que incluye la composición.
BRPI0719972B8 (pt) dispositivo de acesso vascular para deslocamento de fluído estagnado
BRPI0507645A (pt) anticorpo, método de detectar um distúrbio ósseo metabólico, kit para detectar um distúrbio ósseo metabólico, composição farmacêutica para o tratamento de um distúrbio ósseo metabólico, e, método de triar uma substáncia efetiva para tratar e/ou prevenir um distúrbio ósseo metabólico

Legal Events

Date Code Title Description
B25A Requested transfer of rights approved

Owner name: RIBOMIC INC. (JP)

B25A Requested transfer of rights approved

Owner name: RIBOMIC INC. (JP) , FUJIMOTO PHARMACEUTICAL CORPOR

B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 12/01/2021, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 18/09/2009 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF

B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: REFERENTE A 13A ANUIDADE.

B24J Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12)

Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2688 DE 12-07-2022 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.